TWD
CATX icon

True Wealth Design’s Perspective Therapeutics CATX Stock Holding History

True Wealth Design’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222 Buy
+65
New +$246 ﹤0.01% 2428
2025
Q2 		– Sell
-15
Closed -$32 – 2614
2025
Q1 		$32 Buy
+15
New +$45 ﹤0.01% 2493

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

True Wealth Design's CATX Position: Q2 2026 in Review

True Wealth Design opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 65 shares worth $222. The stake represents ﹤0.01% of the portfolio and ranks #2428 among its holdings. This is a return to the name: True Wealth Design previously reported a position in CATX as recently as Q1 2025.

True Wealth Design first reported a position in CATX in Q1 2025 and has held it in 2 quarters since. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • True Wealth Design held 65 shares of Perspective Therapeutics worth $222 as of Q2 2026.
  • Perspective Therapeutics was a new True Wealth Design position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2428 holding.
  • True Wealth Design first reported a position in Perspective Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.